▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3560 by analyst upside · 2026-09-28
WST
West Pharmaceutical Services, Inc.
Healthcare · Market Cap $26B · P/E 47.4x
ANALYST PRICE TARGET
+10.0%
implied upside to consensus target
Current Price $370.44
Consensus Target $407.56
Bull Target $459.0
Bear Target $340.0
Analysts Covering 16
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
11
Hold
1
Sell
0
52-Week Low $223.83
52-Week High $386.0
YTD Return +34.3%
FUNDAMENTALS
Market Cap $26B
P/E Ratio (TTM) 47.4x
Forward P/E 37.1x
EPS (TTM) $7.81
PEG Ratio 2.88
Dividend Yield 0.24%
Revenue (TTM) $3.3B
Profit Margin 17.0%
52-WEEK RANGE
52-Week Low $223.83
52-Week High $386.0
Current Price $370.44
Bear Target $340.0
Bull Target $459.0
● Now $370.44 ● Target $407.56
TRADING DATA
Avg Volume 655K
YTD Return +34.3%
Analyst Count 16
Consensus Buy
Upside to Target +10.0%
Last Updated 2026-09-28

ANALYST SUMMARY

West Pharmaceutical Services, Inc. (WST) is currently trading at $370.44 with a Wall Street consensus price target of $407.56, implying potential upside of 10.0% over the next 12 months. 16 analysts currently cover WST, with a consensus rating of Buy - 94% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $459.0, while the most cautious has a target of $340.0.

WST operates in the Healthcare sector with a market capitalisation of $26B. The stock is up 34.3% year-to-date and is currently trading near the upper end of its 52-week range of $223.83 – $386.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

MTD -3.6%
Mettler-Toledo International Inc.
$30B · P/E 34.1x · Hold
BIIB +4.6%
Biogen Inc.
$34B · P/E 40.5x · Buy
MEDP -6.0%
Medpace Holdings, Inc.
$17B · P/E 36.4x · Hold
IDXX +35.1%
IDEXX Laboratories, Inc.
$41B · P/E 36.5x · Buy
ILMN -24.9%
Illumina, Inc.
$41B · P/E 50.3x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for WST, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Morgan Stanley ↑ Upgrade
Equal-Weight → Overweight 2026-09-22 Building track record
UBS - Reiterated
Buy → Buy 2026-09-09 33% win rate (6 calls)
Citigroup - Reiterated
Buy → Buy 2026-08-03 Building track record
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-07-27 Building track record
BNP Paribas ● Initiated
Outperform 2026-07-13 Building track record
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-07-09 Building track record
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-07-06 Building track record
Keybanc - Reiterated
Overweight → Overweight 2026-07-02 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
68
out of 100
Coverage depth
22/30
Consensus clarity
24/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →